Vertex Pharmaceuticals Incorporated: The Biopharma Powerhouse with Solid Metrics

Vertex Pharmaceuticals: A biopharma behemoth with strong growth and profitability. Dive in for the financial scoop!

WEALTH WORKSHOP

7/6/20231 min read

Hello, savvy investors! Today, we're going to unravel the financial fabric of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader in the biopharmaceutical industry.

Vertex is due to report its Earnings Per Share (EPS) on August 3, 2023. Though the EPS dipped by 13% last quarter, it's not all doom and gloom. Over the past three quarters, the average EPS growth is still in the green at 8.5%. For the current quarter, the EPS is expected to change by 14%, and the last quarter showed a 15.5% earnings surprise. Meanwhile, the company's EPS growth rate over the past three years stands strong at 25%, with a 7% change expected for the current year.

Sales? They're looking good too. The last quarter saw a 13% increase, and the three-year growth rate is a notable 23%. What about profitability? Well, with an annual pre-tax margin of 54.5% and a return on equity (ROE) of 32.1%, Vertex is standing on solid ground. Even the company's debt-to-equity ratio is low, standing at 3%.

On the technical front, the stock price is $351.91, just 1% away from its 52-week high. It is trading 4% above its 50-day moving average, and the average volume over 50 days is 1.3 million shares. The company's market capitalization is a hefty $90.6 billion, with stable fund ownership and six consecutive quarters of increasing fund ownership.

With all these solid metrics, Vertex Pharmaceuticals is one pharmaceutical giant that's worth watching.